Hanmi Science Co., Ltd. engages in the management of its subsidiaries. It is mainly engaged in the manufacturing and selling of pharmaceutical ingredients and intermediates. The company was founded on June 15,1973 and is headquartered in Hwaseong-si, South Korea.

Idemitsu Kosan Co., Ltd. engages in oil, basic chemicals, and renewable energy businesses. It operates through the following segments: Petroleum Products, Petrochemical Products, Resources, and Others. The Petroleum Products segment covers the production and sale of fuel oil and lubricants. The Petrochemical Products segment provides basic chemicals as raw materials for various petrochemical products, as well as solvents and various functional materials. The Resources segment carries out the research, exploration, development, production, and sale of oil, coal, uranium, and geothermal resources. The Others segment includes engineering, electronic materials, insurance, and agricultural biotechnology businesses. The company was founded by Sazo Idemitsu on June 20, 1911 and is headquartered in Tokyo, Japan.

Markets and distributes specialty, artisanal and farmstead cheese products

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded in 1998 based on discoveries arising from over two decades of research in red blood cell substitutes and the mechanisms of oxygen transport by cell-free hemoglobin solutions.

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Araclon Biotech is the scientific investigation, creation, explotation and comercialization of pharmacological and biotechnological products, and the making of diagnostic and pharmacological treatment models, and the explotation and comercialization of them, of owned or others' patents in that field, of the scientific lab activity, of investigation, and of investments in material and immaterial assets or so needed for the activity.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, and commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Jiangsu Zhitai New Energy Technology Co., Ltd., established on 2018-08-22, Business scope includes manufacturing of lithium-ion batteries and accessories,Sales,Install,repair(Does not contain rubber and plastic products);Battery Performance Evaluation Test;Battery Management System Design,Sales;Instrumentation,General Machinery,computer software,Hardware product sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)###### licensed items:Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of new energy vehicle battery replacement facilities;Sales of electric accessories for new energy vehicles;Centralized fast charging station;Battery rental;Communication equipment sales;Distributed AC charging pile sales;Electric Vehicle Charging Infrastructure Operations;Sales of new energy original moving equipment;Distribution switch control equipment sales;Special Equipment Repair;Sales of mobile communication equipment;battery sales;Sales of power electronic components;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Resource recycling technology research and development;Cloud Computing Equipment Manufacturing;Technical extension services;Technology promotion and application services;Environmental protection special equipment sales;General Equipment Repair;Instrument sales;Machinery sales;Machinery and Equipment Leasing;electronics sales;moped bike,Scooter and spare parts sales;High-speed rail equipment,Accessories sales;New material technology research and development;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;business management;Business Management Consulting;Socioeconomic Advisory Services;marketing planning;Engineering Management Services;software development;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);Advertising Design,acting;advertisement making;graphic design;Research and development of high-efficiency and energy-saving technologies in the power industry;Data processing and storage support services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Manufactures pharmaceuticals

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Exxon Chemical Co., a subsidiary of Exxon Mobil Corp., is an American company located in Buffalo Grove, IL, that manufactures and supplies specialty chemicals and provides services for oil and gas production, pipeline and drilling operations.